World's Best Scientists 2026 revealed!
Yoon-Koo Kang

Yoon-Koo Kang

D-Index & Metrics

Medicine

D-Index
103
Citations
68906
World Ranking
7166
National Ranking
15

Overview

Yoon-Koo Kang is affiliated with the University of Ulsan in South Korea. Their research focuses primarily on medicine, with extensive work in oncology, pulmonary and respiratory medicine, gastroenterology, surgery, and hepatology.

The scientist's contributions have been published frequently in several journals. The most common publication venues include:

  • Journal of Clinical Oncology
  • Gastric Cancer
  • Annals of Oncology
  • The Lancet Oncology
  • Cancer Research

Yoon-Koo Kang has collaborated regularly with several researchers, including:

  • Min-Hee Ryu
  • Hyung-Don Kim
  • Keun-Wook Lee
  • Do-Youn Oh
  • Sun Young Rha

Key research topics covered in their work are:

  • Gastric Cancer Management and Outcomes
  • Gastrointestinal Tumor Research and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Colorectal Cancer Treatments and Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Metastasis and carcinoma case studies

Notable recent papers authored or coauthored by Yoon-Koo Kang include:

  • Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial, 2022, The Lancet Oncology
  • Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, 2022, NEJM Evidence
  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib, 2020, JAMA Oncology
  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, 2020, British Journal of Cancer
  • Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial, 2023, The Lancet

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

    Ann Lii Cheng;Yoon Koo Kang;Zhendong Chen;Chao Jung Tsao

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

    Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

    Y.-K. Kang;W.-K. Kang;D.-B. Shin;J. Chen

  • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

    Florian Lordick;Yoon Koo Kang;Hyun Cheol Chung;Pamela Salman

  • Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization

    Paraskevi Giannakakou;Dan L. Sackett;Yoon-Koo Kang;Zhirong Zhan

  • Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    Ann Lii Cheng;Yoon Koo Kang;Deng Yn Lin;Joong Won Park

  • Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

    Muhammad S. Beg;Andrew J. Brenner;Jasgit Sachdev;Mitesh Borad

  • Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

    Josep M. Llovet;Thomas Decaens;Jean-Luc Raoul;Eveline Boucher

  • Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

    Calin Cainap;Shukui Qin;Wen-Tsung Huang;Ik Joo Chung

  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

    David S. Hong;Yoon Koo Kang;Mitesh Borad;Jasgit Sachdev

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

    Eric Van Cutsem;Sanne de Haas;Yoon-Koo Kang;Atsushi Ohtsu

  • SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

    Andrew X. Zhu;Olivier Rosmorduc;T. R Jeffry Evans;Paul J. Ross

  • Management of gastric cancer in Asia: resource-stratified guidelines

    Lin Shen;Yan Shen Shan;Huang Ming Hu;Timothy J. Price

Frequent Co-Authors

Masatoshi Kudo
Masatoshi Kudo Kindai University
Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Ho Yeong Lim
Ho Yeong Lim Samsung Medical Center
Won Ki Kang
Won Ki Kang Samsung Medical Center
Sun Young Rha
Sun Young Rha Yonsei University
Josep M. Llovet
Josep M. Llovet University of Barcelona
Kei Muro
Kei Muro National Cancer Research Institute, UK
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine offers more than just the traditional MD path. Many students consider alternative, flexible options that lead to rewarding healthcare roles. If you want to advance your nursing career or start the journey online, there are affordable and accredited programs available across the United States.

Those seeking advanced practice roles can explore the cheapest np school online options, helping reduce costs while developing critical skills for nurse practitioner jobs. Alternatively, students interested in becoming a registered nurse with a bachelor’s degree can take advantage of cheap rn to bsn online programs for a quick career boost.

There are also affordable nursing programs online for those just beginning their studies and aiming to enter the workforce quickly. For those looking to pursue the pinnacle of nursing education, several reputable phd nursing programs online are available.

Choosing an online degree creates new financial and career possibilities, allowing flexibility, affordability, and the chance to advance in the healthcare sector.

Best Scientists Citing Yoon-Koo Kang

Trending Scientists